AcelRx Pharmaceuticals Inc. (ACRX) Major Shareholder Perceptive Advisors Llc Sells 216,500 Shares
AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) major shareholder Perceptive Advisors Llc sold 216,500 shares of AcelRx Pharmaceuticals stock in a transaction that occurred on Thursday, September 29th. The stock was sold at an average price of $3.92, for a total value of $848,680.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
Perceptive Advisors Llc also recently made the following trade(s):
- On Thursday, September 15th, Perceptive Advisors Llc sold 392,850 shares of AcelRx Pharmaceuticals stock. The stock was sold at an average price of $3.70, for a total value of $1,453,545.00.
Shares of AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) opened at 3.89 on Friday. AcelRx Pharmaceuticals Inc. has a 52-week low of $2.40 and a 52-week high of $5.88. The stock’s market cap is $176.26 million. The firm has a 50-day moving average price of $3.44 and a 200-day moving average price of $3.29.
AcelRx Pharmaceuticals (NASDAQ:ACRX) last issued its earnings results on Thursday, July 28th. The specialty pharmaceutical company reported ($0.24) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.22) by $0.02. AcelRx Pharmaceuticals had a negative net margin of 111.47% and a negative return on equity of 94.98%. The company earned $4.53 million during the quarter, compared to analyst estimates of $2.17 million. On average, analysts anticipate that AcelRx Pharmaceuticals Inc. will post ($0.91) EPS for the current fiscal year.
A number of research firms have weighed in on ACRX. Jefferies Group reissued a “buy” rating on shares of AcelRx Pharmaceuticals in a research note on Friday, June 10th. Zacks Investment Research lowered AcelRx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday. RBC Capital Markets reissued a “positive” rating and set a $6.00 price objective on shares of AcelRx Pharmaceuticals in a research note on Tuesday, August 16th. Cowen and Company reissued a “hold” rating on shares of AcelRx Pharmaceuticals in a research note on Friday, July 29th. Finally, HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of AcelRx Pharmaceuticals in a research note on Thursday, September 8th. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $8.20.
Institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC increased its position in shares of AcelRx Pharmaceuticals by 3.3% in the first quarter. Geode Capital Management LLC now owns 170,734 shares of the specialty pharmaceutical company’s stock valued at $525,000 after buying an additional 5,427 shares in the last quarter. Nippon Life Insurance Co. acquired a new position in shares of AcelRx Pharmaceuticals during the second quarter valued at about $2,247,000. Rhumbline Advisers acquired a new position in shares of AcelRx Pharmaceuticals during the second quarter valued at about $103,000. Schwab Charles Investment Management Inc. acquired a new position in shares of AcelRx Pharmaceuticals during the second quarter valued at about $155,000. Finally, Teachers Advisors Inc. acquired a new position in shares of AcelRx Pharmaceuticals during the second quarter valued at about $157,000. Institutional investors own 35.84% of the company’s stock.
AcelRx Pharmaceuticals Company Profile
AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.
Receive News & Stock Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.